{"id":"apl-130277","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Yawning"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Somnolence"}]},"_chembl":{"chemblId":"CHEMBL4594355","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"APL-130277 is a small-molecule dopamine agonist administered via subcutaneous injection. It crosses the blood-brain barrier and stimulates dopamine receptors, particularly D1 and D2 receptors, to restore dopaminergic neurotransmission in the basal ganglia. This mechanism provides rapid onset of action for acute motor symptom management in Parkinson's disease patients experiencing OFF episodes.","oneSentence":"APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:02:04.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Parkinson's disease, acute OFF episodes"}]},"trialDetails":[{"nctId":"NCT07257861","phase":"","title":"Interest of Continuous Subcutaneous Apomorphine in Parkinsonian Patients at the End of Life","status":"RECRUITING","sponsor":"Centre Hospitalier Régional d'Orléans","startDate":"2026-02-02","conditions":"Parkinson Disease","enrollment":80},{"nctId":"NCT06240390","phase":"NA","title":"Effectiveness of Percutaneous Neuromodulation vs Pharmacological Treatment in Cancer Patients With Anterior Knee Pain","status":"WITHDRAWN","sponsor":"Universidad Europea de Canarias","startDate":"2024-05-01","conditions":"Pain Cancer","enrollment":""},{"nctId":"NCT07422675","phase":"PHASE1","title":"SAD Study in Patients With Parkinson's Disease and Motor Fluctuations","status":"RECRUITING","sponsor":"Serina Therapeutics","startDate":"2026-02-01","conditions":"PARKINSON DISEASE (Disorder), Advanced Parkinson's Disease","enrollment":40},{"nctId":"NCT06954428","phase":"PHASE1","title":"Clinical Trial of Intranasal Delivery of NT-301","status":"COMPLETED","sponsor":"Nano PharmaSolutions Australia","startDate":"2025-06-20","conditions":"Tolerability of NT-301 Nasal Spray, Pharmacokinetics of NT-301 Nasal Spray, Safety of NT-301 Nasal Spray","enrollment":49},{"nctId":"NCT01432821","phase":"NA","title":"Blinking and Yawning in Epilepsy: The Role of Dopamine","status":"COMPLETED","sponsor":"Institut National de la Santé Et de la Recherche Médicale, France","startDate":"2011-09","conditions":"Idiopathic Generalized Epilepsy","enrollment":31},{"nctId":"NCT07402928","phase":"","title":"Optimistic and Pessimistic Dopamine Signals in the Human Brain: a Mapping and Modelling Study in Health and Parkinson's Disease","status":"RECRUITING","sponsor":"Danish Research Centre for Magnetic Resonance","startDate":"2025-06-02","conditions":"Healthy, Parkinson, Medication Administration","enrollment":140},{"nctId":"NCT07145190","phase":"","title":"SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment","status":"RECRUITING","sponsor":"Bial - Portela C S.A.","startDate":"2025-08-27","conditions":"Parkinson Disease","enrollment":90},{"nctId":"NCT07219927","phase":"","title":"Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States:","status":"RECRUITING","sponsor":"Supernus Pharmaceuticals, Inc.","startDate":"2025-03-31","conditions":"Parkinson Disease","enrollment":120},{"nctId":"NCT05979415","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes","status":"TERMINATED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2023-09-27","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT04957095","phase":"NA","title":"Motor Network Physiology","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2022-02-18","conditions":"Parkinson Disease, Essential Tremor","enrollment":120},{"nctId":"NCT02339064","phase":"PHASE3","title":"Infusion of Apomorphine: Long-term Safety Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2015-02","conditions":"Idiopathic Parkinson's Disease","enrollment":99},{"nctId":"NCT04887467","phase":"PHASE4","title":"Monocentric, Prospective Study to Assess the Pharmacokinetic Profile of Continuous and Diurnal Subcutaneous Apomorphine Infusion in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2021-09-16","conditions":"Parkinson Disease","enrollment":19},{"nctId":"NCT05213169","phase":"PHASE2, PHASE3","title":"Apomorphine in Severe Brain-injured Patients","status":"RECRUITING","sponsor":"University of Liege","startDate":"2021-06-18","conditions":"Disorder of Consciousness","enrollment":48},{"nctId":"NCT03911726","phase":"NA","title":"Do Antipsychotic Agents Induce Supersensitivity in Humans: A Combined PET/MRI Study in Patients With Schizophrenia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Central Institute of Mental Health, Mannheim","startDate":"2020-08-01","conditions":"Schizophrenia","enrollment":140},{"nctId":"NCT06080399","phase":"","title":"Personality and Quality of Life Amelioration After Continuous Subcutaneous Apomorphine Infusion in Parkinson's Disease","status":"RECRUITING","sponsor":"University Hospital, Toulouse","startDate":"2024-02-15","conditions":"Parkinson Disease","enrollment":70},{"nctId":"NCT02940912","phase":"PHASE4","title":"Effect of Continuous Apomorphine During the Night on Sleep Disorders in Insomniac Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Clinique Beau Soleil","startDate":"2017-01-31","conditions":"Parkinson Disease","enrollment":45},{"nctId":"NCT02230930","phase":"PHASE2","title":"Treatment of Apomorphine-induced Skin Reactions: a Pilot Study","status":"TERMINATED","sponsor":"University Medical Center Groningen","startDate":"2015-06","conditions":"Parkinson's Disease, Apomorphine-induced Skin Reactions","enrollment":13},{"nctId":"NCT02864004","phase":"PHASE3","title":"Apomorphine Pump in Early Stage of Parkinson's Disease (EARLY-PUMP)","status":"UNKNOWN","sponsor":"Rennes University Hospital","startDate":"2017-03-03","conditions":"Parkinson's Disease","enrollment":134},{"nctId":"NCT03693872","phase":"NA","title":"Evaluation of the Nonmotor Symptomatology of Parkinsonian Patients Treated With Two Strategies Related to Apomorphine Pump Therapy in French Hospitals","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2019-05-15","conditions":"Parkinson Disease","enrollment":43},{"nctId":"NCT02542696","phase":"PHASE3","title":"Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of \"OFF\" Episodes in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-08-31","conditions":"Parkinson Disease","enrollment":496},{"nctId":"NCT02549573","phase":"PHASE4","title":"Outpatient Physical Therapy Intervention in Subjects With Parkinson's Disease Currently Using APOKYN®","status":"TERMINATED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2016-01","conditions":"Parkinson's Disease, Motor Symptoms","enrollment":13},{"nctId":"NCT01770145","phase":"PHASE4","title":"Apokyn for Motor IMProvement of Morning AKinesia Trial (AM IMPAKT)","status":"COMPLETED","sponsor":"MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals","startDate":"2012-12","conditions":"Parkinson's Disease, Motor Symptoms, Akinesia","enrollment":127},{"nctId":"NCT05405998","phase":"NA","title":"Development of a Proactive Health Care Pathway When Initiating Continuous Subcutaneous Apomorphine Infusion in Patients With Parkinson Disease : Impact on Their Autonomy (AUTAP)","status":"UNKNOWN","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2022-12-01","conditions":"Parkinson Disease","enrollment":90},{"nctId":"NCT01039090","phase":"PHASE3","title":"Efficacy of Continuous Apomorphine Infusion on Cognitive and Neuropsychological Functions in Parkinson's Disease","status":"COMPLETED","sponsor":"Rennes University Hospital","startDate":"2009-02","conditions":"Parkinsons's Disease","enrollment":21},{"nctId":"NCT03391882","phase":"PHASE3","title":"A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations (\"OFF\" Episodes)","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2018-12-19","conditions":"Motor OFF Episodes Associated With Parkinson's Disease","enrollment":113},{"nctId":"NCT05529095","phase":"PHASE4","title":"Sublingual Apomorphine in Refractory Restless Legs Syndrome","status":"UNKNOWN","sponsor":"William Ondo, MD","startDate":"2022-09-01","conditions":"Restless Legs Syndrome","enrollment":16},{"nctId":"NCT05331573","phase":"","title":"Parkinsonian Patients Treated With Apomorphine Pump: Observatory of Skin Lesions","status":"UNKNOWN","sponsor":"University Hospital, Rouen","startDate":"2020-10-01","conditions":"Patients With Parkinson's Disease Treated With Apomorphine Pumps","enrollment":108},{"nctId":"NCT04879134","phase":"PHASE2, PHASE3","title":"Apomorphine Effects on Pain in Parkinson's Disease","status":"UNKNOWN","sponsor":"University of Calgary","startDate":"2022-02-28","conditions":"Parkinson Disease","enrollment":40},{"nctId":"NCT05072015","phase":"","title":"Systematic Follow up of Second Line Treatments for Parkinson's Disease (Deep Brain Stimulation, Apomorphin Pump, Duodopa Pump)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-02","conditions":"Parkinson's Disease","enrollment":150},{"nctId":"NCT03623828","phase":"PHASE2","title":"Treating Severe Brain-injured Patients With Apomorphine","status":"UNKNOWN","sponsor":"University of Liege","startDate":"2018-10-03","conditions":"Disorder of Consciousness","enrollment":8},{"nctId":"NCT04441697","phase":"","title":"Sleepiness in Parkinson's Patients With Continuous Dopaminergic Delivery Device or Deep Brain Stimulation","status":"UNKNOWN","sponsor":"Central Hospital, Nancy, France","startDate":"2020-06-01","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT04786158","phase":"","title":"Subcutaneous Apomorphine in the Treatment of Progressive Supranuclear Palsy and Cortico Basal Degeneration (APOPARKA)","status":"COMPLETED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2018-12-01","conditions":"Progressive Supranuclear Palsy, Corticobasal Degeneration","enrollment":7},{"nctId":"NCT04157933","phase":"PHASE1","title":"Staccato Apomorphine Multi-dose PK and PD in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2019-10-16","conditions":"Parkinson's Disease","enrollment":35},{"nctId":"NCT00610103","phase":"PHASE2","title":"Phase 2 Clinical Study of KW-6500 in Parkinson's Disease Patients With Motor Response Complication on Levodopa Therapy","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2007-11","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT03292016","phase":"PHASE2","title":"A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by \"OFF\" Episodes","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-08-22","conditions":"Parkinson Disease","enrollment":8},{"nctId":"NCT03187301","phase":"PHASE2","title":"A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations \"OFF\" Episodes","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2017-08-03","conditions":"Parkinson's Disease, Off Episodes of Parkinson Disease","enrollment":48},{"nctId":"NCT02469090","phase":"PHASE3","title":"Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-06-18","conditions":"Parkinson Disease, Off Episodes","enrollment":141},{"nctId":"NCT02228590","phase":"PHASE2","title":"A Study to Examine APL-130277 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2014-08-31","conditions":"Parkinson's Disease","enrollment":20},{"nctId":"NCT00397748","phase":"","title":"PET Scanning of Adults With Attention Deficit Hyperactivity Disorder (ADHD)","status":"COMPLETED","sponsor":"National Institute of Mental Health (NIMH)","startDate":"2006-09-15","conditions":"Volunteer, Attention Deficit Hyperactivity Disorder","enrollment":16},{"nctId":"NCT03822364","phase":"PHASE1","title":"Staccato Apomorphine Single and Multi Dose PK","status":"COMPLETED","sponsor":"Alexza Pharmaceuticals, Inc.","startDate":"2018-11-26","conditions":"Parkinson Disease","enrollment":56},{"nctId":"NCT00346827","phase":"PHASE2, PHASE3","title":"Apomorphine Nasal Powder in the Treatment of Parkinson's Disease \"Off\" Periods.","status":"COMPLETED","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2006-07","conditions":"Parkinson's Disease","enrollment":36},{"nctId":"NCT02006121","phase":"PHASE3","title":"Clinical Trial of Apomorphine Subcutaneous Infusion in Patients With Advanced Parkinson's Disease","status":"COMPLETED","sponsor":"Britannia Pharmaceuticals Ltd.","startDate":"2014-03-03","conditions":"Parkinson's Disease","enrollment":107},{"nctId":"NCT00489255","phase":"PHASE4","title":"Safety/Efficacy of Tigan® to Control Nausea/Vomiting Experienced During Apokyn® Initiation and Treatment","status":"COMPLETED","sponsor":"Ipsen","startDate":"2007-05","conditions":"Parkinson's Disease","enrollment":117},{"nctId":"NCT03793491","phase":"","title":"Personality, as a Predictive Factor of Therapeutic Response on Quality of Life After Continuous Perfusion of Dopaminergic Drugs, in Parkinson's Disease","status":"UNKNOWN","sponsor":"University Hospital, Toulouse","startDate":"2018-12-18","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT00472355","phase":"PHASE2","title":"Low Dose Apomorphine and Parkinsonism","status":"WITHDRAWN","sponsor":"Oregon Health and Science University","startDate":"2005-10","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT00758368","phase":"PHASE2","title":"Comparison of Continuous and Pulsatile Apomorphine in Parkinson's Disease","status":"WITHDRAWN","sponsor":"Oregon Health and Science University","startDate":"2009-03","conditions":"Parkinson's Disease","enrollment":""},{"nctId":"NCT02688465","phase":"PHASE4","title":"Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).","status":"TERMINATED","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2016-09-05","conditions":"Parkinson's Disease","enrollment":15},{"nctId":"NCT03213379","phase":"NA","title":"Assessment of Actigraphy Procedures on the Initiation of an Apomorphine Treatment Delivered Through a Pump to Patients With Parkinson's Disease","status":"UNKNOWN","sponsor":"Orkyn'","startDate":"2017-07","conditions":"Parkinson Disease","enrollment":190},{"nctId":"NCT02702076","phase":"PHASE2","title":"Apomorphine in Parkinson's Disease Patients With Visual Hallucinations","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2017-05","conditions":"Parkinson's Disease, Hallucinations, Visual","enrollment":35},{"nctId":"NCT00761228","phase":"PHASE2","title":"Efficacy Study of NH001 in Vegetative State & Minimally Conscious State Following a Traumatic Brain Injury","status":"SUSPENDED","sponsor":"NeuroHealing Pharmaceuticals Inc.","startDate":"2010-07","conditions":"Brain Injury","enrollment":76},{"nctId":"NCT00955318","phase":"PHASE3","title":"Long-Term Safety Study of KW-6500 in Patients With Parkinson's Disease","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2009-07","conditions":"Parkinson's Disease","enrollment":58},{"nctId":"NCT01063621","phase":"PHASE3","title":"Extended Long-Term Safety Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":27},{"nctId":"NCT01058291","phase":"PHASE3","title":"Placebo-Controlled Double-Blind Crossover Comparative Study of KW-6500","status":"COMPLETED","sponsor":"Kyowa Kirin Co., Ltd.","startDate":"2010-01","conditions":"Parkinson's Disease","enrollment":31},{"nctId":"NCT01504178","phase":"PHASE3","title":"Evaluation of the Role of the Noradrenergic System in Pain Perception in Parkinson's Disease","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2011-05","conditions":"Parkinson's Disease","enrollment":28},{"nctId":"NCT02969629","phase":"PHASE4","title":"The Effects of Apomorphine on Experimental and Clinical Pain in Patients With Chronic Radicular Pain","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2012-12","conditions":"Chronic Low Back Pain","enrollment":59},{"nctId":"NCT01744964","phase":"EARLY_PHASE1","title":"Apomorphine Effects on Experimental Pain","status":"COMPLETED","sponsor":"Rambam Health Care Campus","startDate":"2009-07","conditions":"Healthy","enrollment":105},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":"Idiopathic Parkinson's Disease","enrollment":679},{"nctId":"NCT01693081","phase":"PHASE2","title":"Phase IIa Multicentre Study Investigating of VR040 in Parkinson's Disease","status":"COMPLETED","sponsor":"South Glasgow University Hospitals NHS Trust","startDate":"2007-03","conditions":"Parkinson's Disease","enrollment":47},{"nctId":"NCT01683292","phase":"PHASE2","title":"Single-Centre Study of VR040(Inhaled Apomorphine) in Idiopathic Parkinson's Disease","status":"COMPLETED","sponsor":"South Glasgow University Hospitals NHS Trust","startDate":"2006-01","conditions":"Parkinson's Disease","enrollment":29},{"nctId":"NCT00437177","phase":"PHASE2","title":"Relationship Between D2 Receptors SPECT and the Apomorphine Test in Patients With OH Dependence (ALC-DRD2-APO)","status":"UNKNOWN","sponsor":"Hospital Universitari Vall d'Hebron Research Institute","startDate":"2007-01","conditions":"Alcoholism","enrollment":50},{"nctId":"NCT00524914","phase":"NA","title":"Apomorphine Effect on Nociceptive Perception in Parkinson's: a Clinical and Imaging Study","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2007-09","conditions":"Parkinson's Disease","enrollment":16},{"nctId":"NCT00040209","phase":"PHASE2","title":"JP-1730 to Treat Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2002-06","conditions":"Parkinson Disease","enrollment":30},{"nctId":"NCT00200512","phase":"PHASE2, PHASE3","title":"Continued Efficacy of Apomorphine After Previous Exposure of at Least Three Months","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-09","conditions":"Parkinson Disease","enrollment":16},{"nctId":"NCT00200525","phase":"PHASE3","title":"Continued Efficacy and Safety of Apomorphine in Patients With Late-Stage Parkinsons Disease","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2001-07","conditions":"Parkinson Disease","enrollment":60},{"nctId":"NCT00145171","phase":"PHASE3","title":"A Sub-Study With Patients in APO401 to Evaluate Adverse Events During Dose Introduction in Apomorphine-naïve Patients.","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"2001-02","conditions":"Parkinson Disease","enrollment":56},{"nctId":"NCT00142545","phase":"PHASE3","title":"Long Term Safety and Efficacy of SC Apomorphine in Treatment of \"Off\" Episodes in Late-Stage Parkinson's Disease","status":"COMPLETED","sponsor":"Mylan Bertek Pharmaceuticals","startDate":"1999-07","conditions":"Parkinson Disease","enrollment":800}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Apomorphine Hydrochloride, Sublingual Thin Film","amomorphine","Apomorphine Hydrochloride"],"phase":"phase_3","status":"active","brandName":"APL-130277","genericName":"APL-130277","companyName":"Sumitomo Pharma America, Inc.","companyId":"sumitomo-pharma-america-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"APL-130277 is a subcutaneous apomorphine formulation that acts as a dopamine agonist to provide rapid symptom relief in Parkinson's disease. Used for Parkinson's disease, acute OFF episodes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":6,"withResults":6},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}